Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

Cancer

Volumn 85, Issue 5, 1999, Pages 1179-1185

  Hainsworth, John D ^a   Burris III, Howard A ^a   Morrissey, Lisa H ^a   Greco, F Anthony ^a  

^a CENTENNIAL MEDICAL CENTER   (United States)

Author keywords

Paclitaxel; Phase I; Refractory cancer; Topotecan

Indexed keywords

CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MELANOMA; MYALGIA; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SMALL CELL CARCINOMA; STOMACH CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CARBOPLATIN; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 0033004505     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990301)85:5<1179::AID-CNCR23>3.0.CO;2-I     Document Type: Article

References (22)

1. Bookman MA, McGuire WP, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-902.
2. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
3. Greco FA, Hainsworth JD. One-hour paclitaxel plus carboplatin for advanced non-small cell lung cancer. Oncology 1998;12(Suppl 2):71-7.
4. Aravantinos G, Athanassiades A, Giannakakis T, Bafaloukos D, Briassoulis E, Kosmidis P, et al. Combination of carboplatin and paclitaxel in anthracycline-resistant advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1997;16: 159A.
5. Dunphy FR, Boyd JH, Kim HJ, Dunphy CH, Harrison BR, Dunleavy TL, et al. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer 1997;79: 2016-23.
6. Meluch AA, Hainsworth JD, Thomas M, Stroup SL, Gray JR, Greco FA. Preoperative therapy with paclitaxel, carboplatin, 5FU, and radiation yields 69% pathologic complete response rate in the treatment of local esophageal carcinoma [abstract]. Proc Am Soc Clin Oncol 1997;16:261A.
7. Redman B, Hussain M, Smith D, Mertens W, Flaherty L. Phase II evaluation of paclitaxel and carboplatin in advanced urothelial cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:325A.
8. Ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
9. Eckardt J, Depierre A, Ardizzoni A, Von Pawel J, Fields S. Pooled analysis of topotecan in the second-line treatment of patients with sensitive small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:452A.
10. Calvert AH, Newell DR, Gumbrell LA. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
11. Schiller JH, von Pawel J, Clarke P, Kleisbauer JP, Dobbs T, Chrysson N, et al. Preliminary results of a randomized comparative phase III trial of topotecan versus CAV as second-line therapy of small cell lung cancer [abstract]. Lung Cancer 1997;18 (Suppl 1):13-4.
12. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996 88:2473-9.
13. Kyritsis A, Newlands ES, Brock CS, Gleason M, Jaeckle K, Levin V, et al. Phase II trial of topotecan as a continuous intravenous infusion in patients with high-grade gliomas [abstract]. Proc Am Soc Clin Oncol 1997;16:394a.
14. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-13.
15. Wiesenfeld M, Marks R, Grill J, Sloan J, Tazelaar H, Carroll T, et al. A randomized phase II study of topotecan and cisplatin with filgrastim (G-CSF) versus topotecan and paclitaxel with filgrastim in patients with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:488a.
16. Miller AA, Hargis JB, Lilenbaum RC, Fields SF, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a Cancer and Leukemia Group B study. J Clin Oncol 1994;12:2743-50.
17. Karato A, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993;11:2030-5.
18. Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, et al. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose intensities. J Clin Oncol 1997;15:3464-77.
19. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with one-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol 1997;15:2385-94.
20. Hainsworth JD, Erland JB, Kalman LA, Hon JK, Smith SW, Greco FA. Phase I/II trial of paclitaxel (1-hour infusion), carboplatin, and gemcitabine in the treatment of advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:471a.
21. Thompson DS, Hainsworth JD, Hopkins LG, Burris HA, Greco FA. Phase I study of vinorelbine, paclitaxel and carboplatin in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:503a.
22. Jett JR, Day R, Levitt M, Woolley G, Jacobs S. Topotecan and paclitaxel in extensive stage small cell lung cancer in patients without prior therapy [abstract]. Lung Cancer 1997;18 (Suppl 1):13.